Hematopoietic Stem Cell TransplantationTransplantation, HomologousPeripheral Blood Stem Cell TransplantationGraft vs Host DiseaseTransplantation, AutologousTransplantation ConditioningBone Marrow TransplantationHematologic NeoplasmsHematopoietic Stem CellsStem Cell TransplantationHematopoietic Stem Cell MobilizationTissue DonorsTreatment OutcomeStem CellsTransplantation ChimeraGraft vs Leukemia EffectBusulfanMyeloablative AgonistsGraft SurvivalHistocompatibilityImmunosuppressive AgentsRecurrenceGranulocyte Colony-Stimulating FactorHistocompatibility TestingRetrospective StudiesWhole-Body IrradiationCord Blood Stem Cell TransplantationAntigens, CD34LeukapheresisLeukemiaVidarabineCombined Modality TherapyGraft vs Tumor EffectHematologic DiseasesChimerismRemission InductionCyclophosphamideCytomegalovirus InfectionsMultiple MyelomaLeukemia, Myeloid, AcuteMyelodysplastic SyndromesBlood Component RemovalSiblingsMelphalanSurvival RateAllograftsHLA AntigensTime FactorsLymphocyte TransfusionSurvival AnalysisPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsDisease-Free SurvivalHematopoiesisOpportunistic InfectionsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveAnemia, AplasticHepatic Veno-Occlusive DiseaseAcute DiseaseSalvage TherapyTransplantation, IsogeneicLymphocyte DepletionTransplantation ImmunologyT-LymphocytesFlow CytometryImmunocompromised HostFollow-Up StudiesCytomegalovirusNeoplasm, ResidualBone Marrow CellsLymphoma, Non-HodgkinCystitisAntilymphocyte SerumFatal OutcomeBlood Group IncompatibilityBlood CellsLymphoproliferative DisordersCell DifferentiationEmbryonic Stem CellsCytarabineBlood DonorsImmunosuppressionLeukemic InfiltrationRisk FactorsMycosesMinor Histocompatibility AntigensBlood Cell CountAdult Stem CellsPrognosisFetal BloodCyclosporineLeukemia, MyeloidGanciclovirEtoposideBone MarrowSevere Combined ImmunodeficiencyProspective StudiesMice, Inbred C57BLMesenchymal Stem Cell TransplantationTransplantation